Reaction
Meningitis Meningococcal reporting signals
As of the last recalculation, Meningitis Meningococcal appears in 165 FAERS reports alongside 3 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 196.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 56 | 196.3 | 196.5 |
| Ravulizumab | 17 | 176.8 | 177.0 |
| Belimumab | 11 | 46.9 | 46.9 |